Joshua D Parsels
Overview
Explore the profile of Joshua D Parsels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1076
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valvo V, Zhang Q, Jiang L, Holcomb E, Pearson A, Edmunds A, et al.
Mol Cancer Ther
. 2024 Dec;
:OF1-OF16.
PMID: 39688341
PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)-mediated antitumoral...
2.
Guo Y, Li Z, Parsels L, Wang Z, Parsels J, Dalvi A, et al.
bioRxiv
. 2024 Sep;
PMID: 39253432
Background: Radiotherapy (RT) is the primary treatment for diffuse midline glioma (DMG), a lethal pediatric malignancy defined by histone H3 lysine 27-to-methionine (H3K27M) mutation. Based on the loss of H3K27...
3.
Zhang Q, Jiang L, Wang W, Huber A, Valvo V, Jungles K, et al.
JCI Insight
. 2024 Feb;
9(6).
PMID: 38376927
Radiotherapy induces a type I interferon-mediated (T1IFN-mediated) antitumoral immune response that we hypothesized could be potentiated by a first-in-class ataxia telangiectasia mutated (ATM) inhibitor, leading to enhanced innate immune signaling,...
4.
Wang W, McMillan M, Zhao X, Wang Z, Jiang L, Karnak D, et al.
Mol Cancer Res
. 2022 Mar;
20(7):1137-1150.
PMID: 35348737
Implications: Our work nominates a novel therapeutic strategy as well as its cellular mechanisms pertinent for future clinical trials combining M3814, radiation, and anti-PD-L1 antibody in patients with pancreatic cancer.
5.
Parsels L, Zhang Q, Karnak D, Parsels J, Lam K, Willers H, et al.
Int J Radiat Oncol Biol Phys
. 2021 Aug;
111(5):e38-e53.
PMID: 34348175
Combination therapies with agents targeting the DNA damage response (DDR) offer an opportunity to selectively enhance the therapeutic index of chemoradiation or eliminate use of chemotherapy altogether. The successful translation...
6.
Zhao K, Zhang Q, Flanagan S, Lang X, Jiang L, Parsels L, et al.
Mol Cancer Res
. 2021 May;
19(9):1571-1582.
PMID: 34045311
Programmed death-ligand 1 (PD-L1) promotes tumor immune evasion by engaging the PD-1 receptor and inhibiting T-cell activity. While the regulation of PD-L1 expression is not fully understood, its expression is...
7.
Cuneo K, Morgan M, Sahai V, Schipper M, Parsels L, Parsels J, et al.
J Clin Oncol
. 2019 Aug;
37(29):2643-2650.
PMID: 31398082
Purpose: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with...
8.
Zhang Q, Green M, Lang X, Lazarus J, Parsels J, Wei S, et al.
Cancer Res
. 2019 May;
79(15):3940-3951.
PMID: 31101760
Combinatorial strategies are needed to overcome the resistance of pancreatic cancer to immune checkpoint blockade (ICB). DNA damage activates the innate immune response and improves ICB efficacy. Because ATM is...
9.
Parsels L, Parsels J, Tanska D, Maybaum J, Lawrence T, Morgan M
Cell Cycle
. 2018 Jun;
17(9):1076-1086.
PMID: 29895190
Small molecule inhibitors of the checkpoint proteins CHK1 and WEE1 are currently in clinical development in combination with the antimetabolite gemcitabine. It is unclear, however, if there is a therapeutic...
10.
Parsels L, Karnak D, Parsels J, Zhang Q, Velez-Padilla J, Reichert Z, et al.
Mol Cancer Res
. 2017 Nov;
16(2):222-232.
PMID: 29133592
KRAS mutations in non-small cell lung cancer (NSCLC) cause increased levels of DNA damage and replication stress, suggesting that inhibition of the DNA damage response (DDR) is a promising strategy...